Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic KRAS confers chemoresistance by upregulating NRF2.

Cancer research - 15 Dec 2014

Tao Shasha, Wang Shue, Moghaddam Seyed Javad, Ooi Aikseng, Chapman Eli, Wong Pak K, Zhang Donna D

Abstract excerpt

Oncogenic KRAS mutations found in 20% to 30% of all non-small cell lung cancers (NSCLC) are associated with chemoresistance and poor prognosis. Here we demonstrate that activation of the cell protective stress response gene NRF2 by KRAS is responsible for its ability to promote drug resistance. RNAi-mediated silencing of NRF2 was sufficient to reverse resistance to cisplatin elicited by ectopic expression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin
Share to Drug Resistance
Share to Gene Silencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to NF-E2-Related Factor 2

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Response Elements

Source

Open in PubMed Open full text

Identifiers

PMID: 25339352
DOI: 10.1158/0008-5472.CAN-14-1439
PMCID: PMC4268230

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic KRAS confers chemoresistance by upregulating NRF2.PMID 25339352Read ↗

Molecular mechanisms and systemic targeting of NRF2 dysregulation in cancer.Semantic proximity Read ↗

Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis.Semantic proximity Read ↗

NRF2 and the Ambiguous Consequences of Its Activation during Initiation and the Subsequent Stages of TumourigenesisSemantic proximity Read ↗

NRF-mediated autophagy and UPR: Exploring new avenues to overcome cancer chemo-resistanceSemantic proximity Read ↗

KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?Semantic proximity Read ↗

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.Semantic proximity Read ↗

Mutant Nrf2E79Q enhances the promotion and progression of a subset of oncogenic Ras keratinocytes and skin tumors.Semantic proximity Read ↗

Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress.Semantic proximity Read ↗

The Dual Roles of NRF2 in Cancer.Semantic proximity Read ↗

NRF2 Participates in the Suppressive Tumor Immune Microenvironment of KRAS/KEAP1 Co-Mutant Non-Small Cell Lung Cancer by Inhibiting the STING PathwaySemantic proximity Read ↗

Distinct Roles for the Thioredoxin and Glutathione Antioxidant Systems in Nrf2-Mediated Lung Tumor Initiation and ProgressionSemantic proximity Read ↗

NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.